Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00315640 · ClinicalTrials.gov registry record · Phase 2
Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation
A Phase 2 study of Eye Diseases, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 12
- Study locations
NCT00315640 is a Phase 2 study of Eye Diseases that has completed, run by Alcon Research. The registered enrollment target is 70 participants, below the 741,300-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The trial reports 12 study locations across 4 states.
The verdict
NCT00315640, a Phase 2 study of Eye Diseases, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of anecortave acetate depot when administered for the treatment of elevated IOP following treatment with steroids.
Conditions Studied
Interventions
- DRUG Anecortave Acetate Sterile Suspension, 60 mg/mL
- OTHER Anecortave Acetate Vehicle
- DRUG Anecortave Acetate Sterile Suspension, 6 mg/mL
- DRUG Anecortave Acetate Suspension Depot, 30 mg/mL
Study Locations (12)
Other
- San Paulo - São Paulo
- Budapest - Budapest
- Padova - Padua
- Amsterdam - Amsterdam
- Bayamon - Bayamón
- Barcelona - Barcelona
- Newcastle upon Tyne - Newcastle upon Tyne
Florida
- Jacksonville - Jacksonville
- Miami - Miami
Texas
- - Fort Worth
- Houston - Houston
Michigan
- Detroit - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2005-12 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00315640
The ClinicalTrials.gov registry entry for NCT00315640 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 741,300-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Eye Diseases appearing as the primary indexed condition, and to 4 interventions - of which Anecortave Acetate Sterile Suspension, 60 mg/mL is the first listed.
NCT00315640 reports 12 study locations spanning 4 distinct geographic areas - top geographies include Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT00315640 about?
NCT00315640 is a clinical study titled "Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation". The purpose of this study is to evaluate the safety and efficacy of anecortave acetate depot when administered for the treatment of elevated IOP following treatment with steroids.
What is the current status of trial NCT00315640?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2005-12. Estimated completion is 2009-07.
What conditions does trial NCT00315640 study?
This clinical trial studies the following conditions: Eye Diseases.
What interventions are being tested in trial NCT00315640?
The interventions under investigation include: Anecortave Acetate Sterile Suspension, 60 mg/mL (DRUG), Anecortave Acetate Vehicle (OTHER), Anecortave Acetate Sterile Suspension, 6 mg/mL (DRUG), Anecortave Acetate Suspension Depot, 30 mg/mL (DRUG).
Who is sponsoring clinical trial NCT00315640?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00315640 being conducted?
This trial has 12 study locations across Florida, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eye Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
RECRUITING · Phase 2
-
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
COMPLETED · Phase 2
-
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.